Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...
Merck and Daiichi Sankyo said a Phase 3 study evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer who received prior EGFR tyrosine ...
A quantitative continuous score identified patients with a TROP2 biomarker likely to respond to the antibody-drug conjugate, a study presented at WCLC showed.